Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 2
1970 1
1971 3
1972 3
1973 1
1975 1
1976 1
1977 1
1978 1
1979 1
1980 4
1981 2
1982 3
1983 5
1984 7
1985 5
1986 8
1987 8
1988 11
1989 6
1990 14
1991 16
1992 7
1993 16
1994 24
1995 41
1996 35
1997 38
1998 35
1999 49
2000 54
2001 43
2002 47
2003 49
2004 61
2005 62
2006 64
2007 46
2008 55
2009 51
2010 39
2011 41
2012 39
2013 43
2014 43
2015 44
2016 40
2017 35
2018 33
2019 26
2020 22
2021 23
2022 18
2023 9
2024 13
2025 14
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,236 results

Results by year

Filters applied: . Clear all
Page 1
Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers.
Pandit S, Biswas S, Jana U, De RK, Mukhopadhyay SC, Biswas TK. Pandit S, et al. Andrologia. 2016 Jun;48(5):570-5. doi: 10.1111/and.12482. Epub 2015 Sep 22. Andrologia. 2016. PMID: 26395129 Clinical Trial.
Treatment with Shilajit for consecutive 90 days revealed that it has significantly (P < 0.05) increased total testosterone, free testosterone and dehydroepiandrosterone (DHEAS) compared with placebo. Gonadotropic hormones (LH and FSH) levels were well maintained....

Treatment with Shilajit for consecutive 90 days revealed that it has significantly (P < 0.05) increased total testosterone, free testoste

…
Effects of carbohydrate reduced diet associated with strength training on clinical signs of women with polycystic ovary syndrome: Randomized clinical trial.
Colonetti L, Uggioni MLR, Prestes GDS, Stangherlin L, Junior JCD, Moura R, Sipriano EDS, Madeira K, Cardoso HS, Ferraz SD, Baptista MM, Grande AJ, Ceretta LB, da Rosa MI, Colonetti T. Colonetti L, et al. Nutrition. 2025 May;133:112696. doi: 10.1016/j.nut.2025.112696. Epub 2025 Jan 31. Nutrition. 2025. PMID: 40048764 Clinical Trial.
We evaluated manifestations of acne, hirsutism by the Ferriman-Gallwey scale and alopecia by the Ludwig-Savin scale, and assessed laboratory tests for total and free testosterone, dehydroepiandrosterone, follicle-stimulating hormone, and luteinizing hormone. The collected …
We evaluated manifestations of acne, hirsutism by the Ferriman-Gallwey scale and alopecia by the Ludwig-Savin scale, and assessed laboratory …
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J. Montesino M, et al. Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6. Gynecol Endocrinol. 2016. PMID: 26634942 Clinical Trial.
The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroepiandrosterone, prasterone) for the treatment of vulvovaginal atrophy (VVA) in women with moderate to severe dyspareunia who were …
The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroep …
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):923-31. doi: 10.1097/gme.0b013e31819e85c6. Menopause. 2009. PMID: 19424093 Clinical Trial.
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local intravaginal application of Prasterone (dehydroepiandrosterone; DHEA) for 12 weeks on the domains of sexual dysfunction, name …
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local …
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18. Climacteric. 2011. PMID: 21244215 Clinical Trial.
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1. METHODS: This prospective, randomized, …
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as …
Monitoring growth during orthodontic treatment.
Ghafari JG, Shofer FS, Laster LL, Markowitz DL, Silverton S, Katz SH. Ghafari JG, et al. Semin Orthod. 1995 Sep;1(3):165-75. doi: 10.1016/s1073-8746(95)80020-4. Semin Orthod. 1995. PMID: 9002913 Clinical Trial.
Every three months, serum levels were measured of the hormone dehydroepiandrosterone sulfate (DHEAS), an androgen associated with growth in midchildhood, and osteocalcin, an indicator of bone turnover. ...
Every three months, serum levels were measured of the hormone dehydroepiandrosterone sulfate (DHEAS), an androgen associated with gro …
Evaluation of biochemical changes and treatment efficacy in patients with bruxism following botulinum toxin or splint therapy: a randomized clinical trial.
Karagozoglu I, Ozcan M. Karagozoglu I, et al. Clin Oral Investig. 2023 Dec 28;28(1):43. doi: 10.1007/s00784-023-05453-w. Clin Oral Investig. 2023. PMID: 38153567 Clinical Trial.
OBJECTIVES: This clinical study aims to analyze the levels of cortisol, dehydroepiandrosterone (DHEA), and tumor necrosis factor alpha (TNF-alpha) in the gingival crevicular fluid (GCF) of persons with bruxism and to compare the efficacy of botulinum toxin (botox) and occl …
OBJECTIVES: This clinical study aims to analyze the levels of cortisol, dehydroepiandrosterone (DHEA), and tumor necrosis factor alph …
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Petri MA, et al. Arthritis Rheum. 2004 Sep;50(9):2858-68. doi: 10.1002/art.20427. Arthritis Rheum. 2004. PMID: 15452837 Clinical Trial.
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms. ...Acne and hirsutism were reported in 33% and 16%, respectively, of the prasterone group and i …
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SL …
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):907-22. doi: 10.1097/gme.0b013e31819e8e2d. Menopause. 2009. PMID: 19436225 Clinical Trial.
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is already decreased by 60% and continues to decline at the time of menopause, the objective of this study was to examine the effect of intravag …
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is a …
Dehydroepiandrosterone replacement in aging humans.
Flynn MA, Weaver-Osterholtz D, Sharpe-Timms KL, Allen S, Krause G. Flynn MA, et al. J Clin Endocrinol Metab. 1999 May;84(5):1527-33. doi: 10.1210/jcem.84.5.5672. J Clin Endocrinol Metab. 1999. PMID: 10323374 Clinical Trial.
Because so much medical and media attention has been drawn to the alleged benefits of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS), it is important to evaluate the effects of replacement therapy objectively using double blind, cross-over, randomized research …
Because so much medical and media attention has been drawn to the alleged benefits of dehydroepiandrosterone (DHEA) and its sulfate e …
1,236 results